Cerevel Therapeutics Holdings Inc (CERE)
39.52
-1.92
(-4.63%)
USD |
NASDAQ |
Jun 25, 16:00
39.52
0.00 (0.00%)
After-Hours: 20:00
Cerevel Therapeutics Holdings Cash from Operations (Quarterly): -119.67M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -119.67M |
| December 31, 2023 | -97.42M |
| September 30, 2023 | -72.63M |
| June 30, 2023 | -77.33M |
| March 31, 2023 | -94.92M |
| December 31, 2022 | -87.48M |
| September 30, 2022 | -80.40M |
| June 30, 2022 | -57.66M |
| March 31, 2022 | -67.65M |
| Date | Value |
|---|---|
| December 31, 2021 | -52.74M |
| September 30, 2021 | -43.78M |
| June 30, 2021 | -45.61M |
| March 31, 2021 | -36.42M |
| December 31, 2020 | -41.70M |
| September 30, 2020 | -20.08M |
| June 30, 2020 | -26.56M |
| March 31, 2020 | -29.45M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-119.67M
Minimum
Mar 2024
-20.08M
Maximum
Sep 2020
-61.85M
Average
-57.66M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
| AbbVie Inc | 4.04B |
| Bristol-Myers Squibb Co | 2.834B |
| Amgen Inc | 689.00M |
| Biogen Inc | 553.20M |
| Reviva Pharmaceuticals Holdings Inc | -11.73M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 19.16M |
| Cash from Financing (Quarterly) | 4.475M |
| Free Cash Flow | -370.79M |
| Free Cash Flow Per Share (Quarterly) | -0.6604 |
| Free Cash Flow Yield | -5.57% |